Medication After Stopping Fosamax
After discontinuing alendronate (Fosamax), the choice of subsequent osteoporosis medication depends critically on your fracture risk status: if you remain at high risk after 3–5 years of treatment, continue with another bisphosphonate (such as zoledronic acid) or switch to denosumab; if your risk has decreased to low-to-moderate, consider a "bisphosphonate holiday" with reassessment every 2–4 years rather than starting a different medication. 1
Risk Reassessment After Alendronate
The decision to continue, switch, or stop therapy hinges on fracture risk reassessment after 3–5 years of alendronate treatment. 1, 2
High-risk patients (those with BMD T-score ≤ -2.5, prior hip or vertebral fracture, or ongoing clinical risk factors) should continue osteoporosis therapy rather than take a drug holiday. 1
Low-to-moderate risk patients may be candidates for a bisphosphonate holiday—a temporary discontinuation for up to 5 years—because alendronate's residual skeletal effects persist after stopping. 1, 3
During a bisphosphonate holiday, reassess fracture risk every 2–4 years and restart therapy earlier if BMD declines significantly, a new fracture occurs, or clinical risk factors worsen. 1
Medication Options for High-Risk Patients Who Must Continue Therapy
Switching to Another Bisphosphonate
Zoledronic acid 5 mg intravenously once yearly is an appropriate alternative for patients who cannot tolerate oral bisphosphonates due to gastrointestinal side effects, malabsorption, or adherence concerns. 1, 4
Zoledronic acid requires adequate hydration, a minimum 15-minute infusion, and is contraindicated when creatinine clearance is below 35 mL/min. 1
Continuing with another oral bisphosphonate (risedronate 35 mg weekly) is also reasonable if the reason for stopping alendronate was not intolerance but rather completion of an initial treatment course. 5
Switching to Denosumab
Denosumab 60 mg subcutaneously every 6 months is the preferred second-line agent for patients with contraindications to or intolerance of bisphosphonates. 1, 6, 4
Denosumab provides superior fracture reduction compared to alendronate in head-to-head studies, with a 39% reduction in major osteoporotic fractures, 36% reduction in hip fractures, and 43% reduction in non-vertebral fractures. 7
Critical safety warning: Denosumab must never be stopped without transitioning to another antiresorptive agent (bisphosphonate, hormone therapy, or SERM) because abrupt discontinuation causes rapid bone loss and rebound vertebral fractures within 6 months. 1, 4, 8
Denosumab does not require dose adjustment for renal insufficiency, but severe renal impairment increases hypocalcemia risk. 4
Ensure calcium and vitamin D adequacy before each denosumab injection, and administer doses precisely every 6 months—delays beyond 1 month increase fracture risk. 4, 8
Switching to Raloxifene (Selective Populations)
Raloxifene 60 mg daily may be considered for younger postmenopausal women (under 60 years or less than 10 years post-menopause) who have low risk of deep vein thrombosis, high breast cancer risk, and for whom bisphosphonates or denosumab are not appropriate. 1, 9, 4
Raloxifene reduces only vertebral fractures—not hip or non-vertebral fractures—and carries risks of venous thromboembolism, pulmonary embolism, and hot flashes. 5
One study demonstrated that raloxifene after long-term alendronate prevented lumbar spine BMD loss (-0.75% at 12 months vs. -2.66% with placebo) and moderated bone turnover increases, though alendronate continuation was more effective. 10
Anabolic Therapy for Very High-Risk Patients
Teriparatide 20 µg subcutaneously daily or abaloparatide should be considered for very high-risk patients (multiple or severe vertebral fractures, fracture while on bisphosphonate therapy, or T-score ≤ -3.0 with additional risk factors) to maximize early fracture-risk reduction. 1, 4
After completing up to 2 years of anabolic therapy, patients must transition to an antiresorptive agent (bisphosphonate, denosumab, hormone therapy, or SERM) to preserve bone density gains. 1, 4
What Happens If You Stop Without Replacement Therapy
Discontinuing alendronate without replacement leads to gradual BMD decline (lumbar spine -2.66% at 12 months, though total hip BMD remains stable) and increased bone turnover markers, but fracture risk does not significantly increase for most patients over 5 years—except for clinical vertebral fractures, which do increase. 10, 3
Women at very high risk of clinical vertebral fractures benefit from continuing beyond 5 years rather than taking a holiday. 3
Bone turnover markers rise after stopping alendronate but remain somewhat below pretreatment levels even after 5 years off therapy, reflecting alendronate's prolonged skeletal retention. 3
Pre-Treatment Requirements for Any New Medication
Ensure total calcium intake of 1,000–1,200 mg daily from diet plus supplements. 4
Provide vitamin D supplementation of 800–1,000 IU daily. 4
Correct any hypocalcemia before initiating bisphosphonates or denosumab. 4
For denosumab specifically, perform a comprehensive dental examination and complete any needed invasive dental procedures before starting therapy to minimize osteonecrosis of the jaw risk. 8
Common Pitfalls to Avoid
Stopping denosumab without transition therapy is the most dangerous error in osteoporosis management, causing rapid bone loss and rebound vertebral fractures. 1, 4, 8
Using anabolic agents without a planned antiresorptive follow-up results in loss of bone-density gains. 1, 4
Allowing denosumab dosing delays beyond 6 months increases fracture risk; delays of 3–6 months raise the fracture hazard ratio to approximately 1.9. 8
Failing to reassess fracture risk after 3–5 years of bisphosphonate therapy means missing the opportunity to either safely discontinue therapy in low-risk patients or intensify treatment in those who remain high-risk. 1, 2